Molecular mechanism of sphingosine-1-phosphate action in Duchenne muscular dystrophy

DMM Disease Models and Mechanisms

Volumn 7, Issue 1, 2014, Pages 41-54

  Nguyen Tran, Diem Hang ^a,b,c   Hait, Nitai C ^d   Sperber, Henrik ^a,b,c   Qi, Junlin ^b,c   Fischer, Karin ^b,c   Ieronimakis, Nick ^a   Pantoja, Mario ^b,c   Hays, Aislinn ^a,b   Allegood, Jeremy ^d   Reyes, Morayma ^a,b   Spiegel, Sarah ^d   Ruohola Baker, Hannele ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dys; Dystrophin; HDAC; Mdx; S1P; THI

Indexed keywords

2 ACETYL 5 TETRAHYDROXYBUTYL IMIDAZOLE; CONNECTIN; FATTY ACID; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; IMIDAZOLE DERIVATIVE; MICRORNA 1; MICRORNA 29; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL REGENERATION; CHROMOSOME CONDENSATION; CHROMOSOME SEGREGATION; CONTROLLED STUDY; DIAPHRAGM; DOWN REGULATION; DROSOPHILA; DUCHENNE MUSCULAR DYSTROPHY; ENERGY METABOLISM; ENERGY RESOURCE; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID METABOLISM; GENE EXPRESSION; HISTONE ACETYLATION; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MITOCHONDRIAL RESPIRATION; MOUSE; MUSCLE CELL; MUSCLE INJURY; MUSCLE METABOLISM; MUSCLE STRENGTH; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; UPREGULATION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

DYS; DYSTROPHIN; HDAC; MDX; S1P; THI;

ACETYLATION; ALDEHYDE-LYASES; ANIMALS; CELL NUCLEUS; DOWN-REGULATION; HISTONE DEACETYLASES; HISTONES; IMIDAZOLES; INFLAMMATION; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MICRORNAS; MITOCHONDRIA; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROTEIN KINASES; REGENERATION; SARCOMERES; SPHINGOSINE; TISSUE DISTRIBUTION;

EID: 84892397094     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.013631     Document Type: Article

References (63)

1. Au, C. G., Butler, T. L., Sherwood, M. C., Egan, J. R., North, K. N. and Winlaw, D. S. (2011). Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int. J. Exp. Pathol. 92, 57-65.
2. Bagdanoff, J. T., Donoviel, M. S., Nouraldeen, A., Tarver, J., Fu, Q., Carlsen, M., Jessop, T. C., Zhang, H., Hazelwood, J., Nguyen, H. et al. (2009). Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J. Med. Chem. 52, 3941-3953.
3. Barresi, R. and Campbell, K. P. (2006). Dystroglycan: from biosynthesis to pathogenesis of human disease. J. Cell Sci. 119, 199-207.
4. Bentzinger, C. F., Wang, Y. X., von Maltzahn, J., Soleimani, V. D., Yin, H. and Rudnicki, M. A. (2013). Fibronectin regulates Wnt7a signaling and satellite cell expansion. Cell Stem Cell 12, 75-87.
5. Blake, D. J., Weir, A., Newey, S. E. and Davies, K. E. (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291-329.
6. Brenman, J. E., Chao, D. S., Xia, H., Aldape, K. and Bredt, D. S. (1995). Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82, 743-752.
7. Bruni, P. and Donati, C. (2008). Pleiotropic effects of sphingolipids in skeletal muscle. Cell. Mol. Life Sci. 65, 3725-3736.
8. Bruni, P. and Donati, C. (2013). Role of sphingosine 1-phosphate in skeletal muscle cell biology. Handbook Exp. Pharmacol. 216, 457-467.
9. Cacchiarelli, D., Martone, J., Girardi, E., Cesana, M., Incitti, T., Morlando, M., Nicoletti, C., Santini, T., Sthandier, O., Barberi, L. et al. (2010). MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab. 12, 341-351.
10. Caldow, M. K., Steinberg, G. R. and Cameron-Smith, D. (2011). Impact of SOCS3 overexpression on human skeletal muscle development in vitro. Cytokine 55, 104-109.
11. Chemello, F., Bean, C., Cancellara, P., Laveder, P., Reggiani, C. and Lanfranchi, G. (2011). Microgenomic analysis in skeletal muscle: expression signatures of individual fast and slow myofibers. PLoS ONE 6, e16807.
12. Chen, Y. W., Zhao, P., Borup, R. and Hoffman, E. P. (2000). Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J. Cell Biol. 151, 1321-1336.
13. Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. M., Conlon, F. L. and Wang, D. Z. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38, 228-233.
14. Christoforou, C. P., Greer, C. E., Challoner, B. R., Charizanos, D. and Ray, R. P. (2008). The detached locus encodes Drosophila Dystrophin, which acts with other components of the Dystrophin Associated Protein Complex to influence intercellular signalling in developing wing veins. Dev. Biol. 313, 519-532.
15. Cocco, L., Maraldi, N. M., Manzoli, F. A., Gilmour, R. S. and Lang, A. (1980). Phospholipid interactions in rat liver nuclear matrix. Biochem. Biophys. Res. Commun. 96, 890-898.
16. Colussi, C., Mozzetta, C., Gurtner, A., Ill, B., Rosati, J., Straino, S., Ragone, G., Pescatori, M., Zaccagnini, G., Antonini, A. et al. (2008). HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. USA 105, 19183-19187.
17. Consalvi, S., Mozzetta, C., Bettica, P., Germani, M., Fiorentini, F., Del Bene, F., Rocchetti, M., Leoni, F., Monzani, V., Mascagni, P. et al. (2013). Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol. Med. 19, 79-87.
18. Dhume, A., Lu, S. and Horowits, R. (2006). Targeted disruption of N-RAP gene function by RNA interference: a role for N-RAP in myofibril organization. Cell Motil. Cytoskeleton 63, 493-511.
19. English, K. M. and Gibbs, J. L. (2006). Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders. Dev. Med. Child Neurol. 48, 231-235.
20. Facucho-Oliveira, J. M., Alderson, J., Spikings, E. C., Egginton, S. and St John, J. C. (2007). Mitochondrial DNA replication during differentiation of murine embryonic stem cells. J. Cell Sci. 120, 4025-4034.
21. Fairclough, R. J., Wood, M. J. and Davies, K. E. (2013). Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat. Rev. Genet. 14, 373-378.
22. Friedrich, O., Both, M., Weber, C., Schürmann, S., Teichmann, M. D., von Wegner, F., Fink, R. H., Vogel, M., Chamberlain, J. S. and Garbe, C. (2010). Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle. Biophys. J. 98, 606-616.
23. Galmozzi, A., Mitro, N., Ferrari, A., Gers, E., Gilardi, F., Godio, C., Cermenati, G., Gualerzi, A., Donetti, E., Rotili, D. et al. (2013). Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes 62, 732-742.
24. Gramolini, A. O., Bélanger, G., Thompson, J. M., Chakkalakal, J. V. and Jasmin, B. J. (2001). Increased expression of utrophin in a slow vs. a fast muscle involves posttranscriptional events. Am. J. Physiol. 281, C1300-C1309.
25. Granzier, H. L. and Labeit, S. (2006). The giant muscle protein titin is an adjustable molecular spring. Exerc. Sport Sci. Rev. 34, 50-53.
26. Hait, N. C., Allegood, J., Maceyka, M., Strub, G. M., Harikumar, K. B., Singh, S. K., Luo, C., Marmorstein, R., Kordula, T., Milstien, S. et al. (2009). Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325, 1254-1257.
27. Hinkle, R. T., Lefever, F. R., Dolan, E. T., Reichart, D. L., Dietrich, J. A., Gropp, K. E., Thacker, R. I., Demuth, J. P., Stevens, P. J., Qu, X. A. et al. (2007). Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice. BMC Med. 5, 18.
28. Ieronimakis, N., Pantoja, M., Hays, A., Dosey, T., Qi, J., Fischer, K., Hoofnagle, A., Sadilek, M., Chamberlain, J., Ruohola-Baker, H. et al. (2013). Increased Sphingosine-1-Phosphate ameliorates disease pathology in mdx mice after acute injury. Skelet. Muscle 3, 20.
29. Ihlefeld, K., Claas, R. F., Koch, A., Pfeilschifter, J. M. and Meyer Zu Heringdorf, D. (2012). Evidence for a link between histone deacetylation and Ca2+ homoeostasis in sphingosine-1-phosphate lyase-deficient fibroblasts. Biochem. J. 447, 457-464.
30. Ishizaki, M., Suga, T., Kimura, E., Shiota, T., Kawano, R., Uchida, Y., Uchino, K., Yamashita, S., Maeda, Y. and Uchino, M. (2008). Mdx respiratory impairment following fibrosis of the diaphragm. Neuromuscular Disorders 18, 342-348.
31. Kenyon, N. J., Ward, R. W., McGrew, G. and Last, J. A. (2003). TGF-beta1 causes airway fibrosis and increased collagen I and III mRNA in mice. Thorax 58, 772-777.
32. Kiernan, J. (2008). Histological and Histochemical Methods: Theory and Practice, 4th edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
33. Knight, P. J. and Trinick, J. A. (1982). Preparation of myofibrils. Methods Enzymol. 85B, 9-12.
34. Kotelnikova, E., Shkrob, M. A., Pyatnitskiy, M. A., Ferlini, A. and Daraselia, N. (2012). Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy. PLOS Comput. Biol. 8, e1002365.
35. Kucherenko, M. M., Pantoja, M., Yatsenko, A. S., Shcherbata, H. R., Fischer, K. A., Maksymiv, D. V., Chernyk, Y. I. and Ruohola-Baker, H. (2008). Genetic modifier screens reveal new components that interact with the Drosophila dystroglycandystrophin complex. PLoS ONE 3, e2418.
36. Lai, K. M., Gonzalez, M., Poueymirou, W. T., Kline, W. O., Na, E., Zlotchenko, E., Stitt, T. N., Economides, A. N., Yancopoulos, G. D. and Glass, D. J. (2004). Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol. Cell. Biol. 24, 9295-9304.
37. Lapidos, K. A., Kakkar, R. and McNally, E. M. (2004). The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ. Res. 94, 1023-1031.
38. Le Rumeur, E., Winder, S. J. and Hubert, J. F. (2010). Dystrophin: more than just the sum of its parts. Biochim. Biophys. Acta 1804, 1713-1722.
39. Li, D., Bareja, A., Judge, L., Yue, Y., Lai, Y., Fairclough, R., Davies, K. E., Chamberlain, J. S. and Duan, D. (2010). Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. J. Cell Sci. 123, 2008-2013.
40. Loh, K. C., Leong, W. I., Carlson, M. E., Oskouian, B., Kumar, A., Fyrst, H., Zhang, M., Proia, R. L., Hoffman, E. P. and Saba, J. D. (2012). Sphingosine-1-phosphate enhances satellite cell activation in dystrophic muscles through a S1PR2/STAT3 signaling pathway. PLoS ONE 7, e37218.
41. Maceyka, M., Harikumar, K. B., Milstien, S. and Spiegel, S. (2012). Sphingosine-1- phosphate signaling and its role in disease. Trends Cell Biol. 22, 50-60.
42. Mamo, S., Gal, A. B., Bodo, S. and Dinnyes, A. (2007). Quantitative evaluation and selection of reference genes in mouse oocytes and embryos cultured in vivo and in vitro. BMC Dev. Biol. 7, 14.
43. Matsumura, K., Shimizu, T., Nonaka, I. and Mannen, T. (1989). Immunochemical study of connectin (titin) in neuromuscular diseases using a monoclonal antibody: connectin is degraded extensively in Duchenne muscular dystrophy. J. Neurol. Sci. 93, 147-156.
44. Minetti, G. C., Colussi, C., Adami, R., Serra, C., Mozzetta, C., Parente, V., Fortuni, S., Straino, S., Sampaolesi, M., Di Padova, M. et al. (2006). Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 12, 1147-1150.
45. Nagata, Y., Partridge, T. A., Matsuda, R. and Zammit, P. S. (2006). Entry of muscle satellite cells into the cell cycle requires sphingolipid signaling. J. Cell Biol. 174, 245-253.
46. Niebroj Dobosz, I., Fidzianska, A. and Glinka, Z. (1997). Comparative studies of hind limb and diaphragm muscles of mdx mice. Basic Appl. Myol. 7, 381-386.
47. Pantoja, M. and Ruohola-Baker, H. (2013). Drosophila as a starting point for developing therapeutics for the rare disease Dunchenne Muscular Dystrophy. Rare Dis. 1, e24995.
48. Pantoja, M., Fischer, K. A., Ieronimakis, N., Reyes, M. and Ruohola-Baker, H. (2013). Genetic elevation of sphingosine 1-phosphate suppresses dystrophic muscle phenotypes in Drosophila. Development 140, 136-146.
49. Rapizzi, E., Donati, C., Cencetti, F., Nincheri, P. and Bruni, P. (2008). Sphingosine 1-phosphate differentially regulates proliferation of C2C12 reserve cells and myoblasts. Mol. Cell. Biochem. 314, 193-199.
50. Reddy, V. S., Valente, A. J., Delafontaine, P. and Chandrasekar, B. (2011). Interleukin-18/WNT1-inducible signaling pathway protein-1 signaling mediates human saphenous vein smooth muscle cell proliferation. J. Cell. Physiol. 226, 3303-3315.
51. Roof, D. J., Hayes, A., Adamian, M., Chishti, A. H. and Li, T. (1997). Molecular characterization of abLIM, a novel actin-binding and double zinc finger protein. J. Cell Biol. 138, 575-588.
52. Rosen, H., Gonzalez-Cabrera, P. J., Sanna, M. G. and Brown, S. (2009). Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem. 78, 743-768.
53. Schiaffino, S. and Reggiani, C. (2011). Fiber types in mammalian skeletal muscles. Physiol. Rev. 91, 1447-1531.
54. Schwab, S. R., Pereira, J. P., Matloubian, M., Xu, Y., Huang, Y. and Cyster, J. G. (2005). Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309, 1735-1739.
55. Selsby, J. T., Morine, K. J., Pendrak, K., Barton, E. R. and Sweeney, H. L. (2012). Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS ONE 7, e30063.
56. Song, X. M., Ryder, J. W., Kawano, Y., Chibalin, A. V., Krook, A. and Zierath, J. R. (1999). Muscle fiber type specificity in insulin signal transduction. Am. J. Physiol. 277, R1690-R1696.
57. Strub, G. M., Paillard, M., Liang, J., Gomez, L., Allegood, J. C., Hait, N. C., Maceyka, M., Price, M. M., Chen, Q., Simpson, D. C. et al. (2011). Sphingosine-1- phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J. 25, 600-612.
58. Subramaniam, S., Sreenivas, P., Cheedipudi, S., Reddy, V. R., Shashidhara, L. S., Chilukoti, R. K., Mylavarapu, M. and Dhawan, J. (2013). Distinct transcriptional networks in quiescent myoblasts: a role for Wnt signaling in reversible vs. irreversible arrest. PLoS ONE 8, e65097.
59. Tea, J. S., Chihara, T. and Luo, L. (2010). Histone deacetylase Rpd3 regulates olfactory projection neuron dendrite targeting via the transcription factor Prospero. Neuroscience 30, 9939-9946.
60. Tinsley, J., Deconinck, N., Fisher, R., Kahn, D., Phelps, S., Gillis, J. M. and Davies, K. (1998). Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 4, 1441-1444.
61. von Maltzahn, J., Renaud, J. M., Parise, G. and Rudnicki, M. A. (2012). Wnt7a treatment ameliorates muscular dystrophy. Proc. Natl. Acad. Sci. USA 109, 20614-20619.
62. Wang, L., Zhou, L., Jiang, P., Lu, L., Chen, X., Lan, H., Guttridge, D. C., Sun, H. and Wang, H. (2012). Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol. Ther. 20, 1222-1233.
63. Webster, C., Silberstein, L., Hays, A. P. and Blau, H. M. (1988). Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 52, 503-513.